Biologics vs. JAK Inhibitors for Atopic Dermatitis: Which One Wins for Your Patient? A 2026 Practical Guide

Atopic Dermatitis (AD) remains a burdensome chronic inflammatory skin condition affecting quality of life, often accompanied by comorbidities such as asthma, allergic rhinitis, or food allergies. While most patients respond to topicals, 10 -30% require systemic therapy. The review article in JACI  goes over targeted options beyond older immunosuppressants (e.g., cyclosporine, methotrexate), focusing on:

Biologics (monoclonal antibodies targeting type 2 inflammation):

- Dupilumab (blocks IL-4/IL-13) - widely used, approved from 6 months of age, strong for comorbid asthma or other type 2 diseases, but can cause conjunctivitis.

- Tralokinumab and lebrikizumab (IL-13 specific) - similar efficacy, potentially better ocular tolerability.

- Nemolizumab (targets IL-31) - stands out for rapid itch (pruritus) relief.

The biologics requires subcutaneous injections, have slower onset (4–8 weeks), but also require minimal lab monitoring, and have a generally favorable safety in patients with cardiovascular risks, infections, or malignancy history.

Janus Kinase (JAK) Inhibitors (oral, daily dosing):

- Abrocitinib, upadacitinib (primarily JAK1 selective), baricitinib (JAK1/2).

JAK inhibitors have faster onset and often superior short-term efficacy (especially high doses) in reducing eczema severity (EASI), itch (PP-NRS), and quality-of-life scores (DLQI/POEM), per network meta-analysis rankings.

However, they carry boxed warnings and require regular monitoring (CBC, lipids, liver function, infection screening) due to risks like venous thromboembolism (VTE), serious infections, herpes zoster, acne, nausea, and potential long-term concerns (malignancy). An elevated malignancy risk has been reported, although for abrocitinib, baricitinib, and upadacitinib the overall incidence remains low. They are contraindicated in pregnancy/breastfeeding.

The authors provide a stepped-care algorithm (starting with adherence, trigger avoidance, and phototherapy if possible), an "option grid" comparing factors side-by-side, and guidance on response evaluation (aim for clear improvement by 3 months, optimal by 6 months), tapering (possible with good control, especially biologics via extended intervals), and switching therapies.

Treatment choice is highly individualized:

Prefer biologics for patients with significant comorbidities, younger children, or when minimizing monitoring/risk is key.

Consider JAK inhibitors for rapid control of severe flares or when oral convenience and higher peak efficacy matter most.

Shared decision-making, considering patient preferences, age, comorbidities, and practical factors (injection vs. pill, monitoring burden), is essential. 

References:

https://www.jaci-inpractice.org/article/S2213-2198(25)01121-3/fulltext